RenovoRx Balances Device Sales with Pancreatic Cancer Trial Hope

MOUNTAIN VIEW, CA – March 20, 2026 – As RenovoRx, Inc. prepares to host its fourth quarter and full-year 2025 financial results conference call on March 30, the life sciences company finds itself at a critical juncture, navigating a dual strategy that has investors and the medical community watching closely. The Nasdaq-listed firm (RNXT) is simultaneously pushing the commercial adoption of its FDA-cleared RenovoCath device while advancing a pivotal Phase III clinical trial that offers a glimmer of hope for patients with one of the deadliest cancers.

Management is expected to detail its progress on both fronts, providing updates that will be scrutinized for signs of commercial traction, clinical advancement, and the overall financial health of a company tackling a high-risk, high-reward field. The call will serve as a key barometer for RenovoRx’s unique business model: using early-stage device revenue to help fuel the long and costly path of oncology drug development.

A Dual Strategy: Commercializing a Device to Fund a Cure

Unlike many clinical-stage biotechnology companies that operate for years without revenue, RenovoRx has begun to generate income through its RenovoCath delivery system. For the first nine months of 2025, the company reported approximately $900,000 in revenue from the sale of this specialized catheter, which is designed for the targeted delivery of therapies. This figure, while modest, represents a significant milestone, with the first commercial orders having been placed only in December 2024.

The adoption of RenovoCath is gaining momentum in prestigious U.S. cancer centers. The company has expanded its partnerships from five to at least nine institutions, including renowned National Cancer Institute-designated centers like City of Hope and Moffitt Cancer Center. This growing roster of clients, some of whom have already placed repeat orders, validates the clinical utility of the device as a standalone product and provides a foundational revenue stream.

However, this income is set against the backdrop of significant operational costs. RenovoRx posted a net loss of $8.2 million for the first nine months of 2025, a figure reflective of the heavy investment required for research, development, and clinical trials. The company's strategy appears to be one of reinvesting its early commercial gains and investor capital into its broader mission. To accelerate market penetration, RenovoRx plans to strategically build out a dedicated sales and marketing team, a move intended to capitalize on an estimated $400 million peak annual market for RenovoCath in the U.S. alone.

In the Trenches Against Pancreatic Cancer

At the heart of RenovoRx's long-term vision is the Phase III TIGeR-PaC clinical trial, a study that could redefine treatment for locally advanced pancreatic cancer (LAPC). Pancreatic cancer remains one of the most challenging malignancies, with a five-year survival rate hovering at a grim 12%. For LAPC patients, survival is often measured in months, not years, and therapeutic advancements have been painfully slow over the past decade.

The TIGeR-PaC trial is evaluating a novel drug-device combination: the chemotherapeutic agent gemcitabine delivered directly to the tumor via the RenovoCath. This approach, part of the company's proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, is designed to bathe the tumor in high concentrations of the drug while minimizing the debilitating systemic toxicities of conventional intravenous chemotherapy.

Encouragingly, the trial is progressing on schedule. RenovoRx expects to complete patient enrollment in the first half of 2026, with final data anticipated in 2027. A significant vote of confidence came in 2025 when an independent Data Monitoring Committee (DMC), after a second interim analysis, recommended the study continue as planned. Such recommendations are often seen as positive indicators that a trial is not demonstrating futility or undue safety risks.

Further bolstering its potential, the drug-device combination, known as IAG, has received Orphan Drug Designation from the FDA for both pancreatic and bile duct cancer. This status provides valuable incentives, including potential market exclusivity for seven years upon approval, recognizing the urgent need for new treatments in these rare and difficult-to-treat diseases.

Navigating Investor Expectations and Market Realities

For investors, RenovoRx presents a complex picture of promising science coupled with financial risk. Analyst sentiment is notably bullish, with a consensus “Strong Buy” rating and an average price target of $8.00, suggesting significant upside from its recent trading range. The company’s stock has fluctuated between $0.701 and $1.450 over the past 52 weeks, highlighting the volatility inherent in the sector.

Despite the positive long-term outlook from analysts, the market has shown caution. Following the third-quarter 2025 earnings announcement, the company's stock dipped after a revenue miss against analyst expectations. To strengthen its financial position for the critical period ahead, RenovoRx recently announced a $10 million at-market private placement on March 18, 2026. This infusion, combined with the $10 million in cash reported at the end of the third quarter, is intended to fund the RenovoCath commercial scale-up and continued progress in the TIGeR-PaC trial.

The upcoming conference call will be a pivotal moment for management to reassure investors, align expectations, and articulate a clear path forward. Stakeholders will be listening for details on revenue growth, expense management, and any further insights into the clinical trial's trajectory.

The Road Ahead: Data, Adoption, and Platform Expansion

Looking beyond the TIGeR-PaC trial, RenovoRx is strategically laying the groundwork to broaden the applications of its TAMP™ platform. The company is actively supporting post-marketing registry studies and investigator-initiated trials (IITs) in other areas, such as borderline resectable and metastatic pancreatic cancer. This approach represents a capital-efficient strategy for data generation, leveraging external research to explore the technology's potential in other solid tumors without bearing the full cost of company-sponsored trials.

As the company approaches its March 30th update, it stands on two parallel tracks: one focused on the immediate, tangible goal of increasing device sales, and the other on the long-term, transformative potential of its clinical pipeline. The success of RenovoRx may ultimately depend on its ability to expertly manage both, using the commercial wins of today to finance the cancer treatment breakthroughs of tomorrow.